Related Experiment Video
Updated: May 24, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
Continuous DNA methylation deconvolution-based surrogate for B-cell differentiation state in chronic lymphocytic
Jeffrey Hage1,2, Lauren Wainman3, Fiyinfoluwa Kolawole1,2
1Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.
Background:
Chronic lymphocytic leukemia (CLL) is clinically divided categorically into IGHV mutated (M-CLL) and IGHV unmutated (U-CLL) subtypes. We aimed to generate a continuous metric of CLL epigenetic state to correspond to the many steps of B-cell differentiation from which CLL neoplasms may arise.
Methods:
We measured genome-scale DNA methylation in purified CLL samples (n = 89) and utilized reference-based cell deconvolution techniques to develop a continuous metric of epigenetic similarity across a B-naive-like to B-memory-like scale (B-Index). We used B-Index to find epigenome-wide changes across CLL differentiation states. We also analyzed the epigenetic similarity of U-CLL to normal B-cell types, and epigenetic correlates of tumor burden.
Results:
We find that B-Index accurately classifies CLL into clinical subtypes (98.8%), has a stronger epigenetic signal than IGHV gene percent identity, and demonstrates additional epigenetic signal within clinical subgroups. We demonstrate that U-CLL is epigenetically more similar to B-memory than B-naive cells and reconcile previous reports of a B-naive-like epigenetic signal. The B-memory-like program of U-CLL is enriched for binding sites of transcription factors related to the germinal center activation pathway. We also identified an epigenetic signal associated with tumor burden, which was enriched for binding sites of Epstein-Barr-Virus transcription factors.
Conclusions:
Our analyses show that more epigenetic states are present among CLL neoplasms than are captured by the clinical classification system. Our approach can be used to generate continuous metrics of epigenetic states for other neoplasms.

